NCT00249574View on ClinicalTrials.gov

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

March 31, 2004

Study Completion Date

June 30, 2006

Conditions
Hepatitis CHeroin Dependence
Interventions
DRUG

Buprenorphine/naloxone

Human subjects HIV, HCV

DRUG

pegInterferon

intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.

Trial Locations (1)

94612

O.A.S.I.S., Oakland

All Listed Sponsors
collaborator

Organization to Achieve Solutions in Substance Abuse (OASIS)

OTHER

lead

National Institute on Drug Abuse (NIDA)

NIH

NCT00249574 - Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1 | Biotech Hunter | Biotech Hunter